Skip to content
The Great Grantsby G

Research Council of Norway

Cell and Gene Therapy for Personalised Medicine

Deadline: 20 January 2027 (in 87 days)

Pre-proposal deadline; call opens 4 November 2026; full proposal deadline 25 May 2027

Last seen in a scan/import: .

Catalog updated: .

These timestamps are not source verification. Confirm the current deadline and your eligibility on the funder’s call page before applying.

Closes 20 Jan 2027. Add it to your calendar, then see what else you're eligible for. Check my fit for this call →

This Research Council of Norway call, run through the EP PerMed partnership, funds interdisciplinary and cross-sectorial research consortia developing and validating cell and gene therapy approaches for personalised medicine, at technology readiness levels 3-6. It is a one-off call open to Norwegian participants in cross-national consortia, structured as a two-stage application process.

Details

Funder Research Council of Norway
Deadline 20 January 2027
Consortium Required — interdisciplinary, cross-sectoral research consortium under EP PerMed
Application 2-stage: pre-proposal (20 January 2027) → full proposal (25 May 2027)
TRL 3-6
Frequency Annual
Eligible countries NO

Eligibility & scope

Encourages interdisciplinary and cross-sectoral research collaborations on developing and validating innovative cell and gene therapy for personalised medicine, under the European Partnership for Personalised Medicine (EP PerMed).

Who Should Apply

  • •Researchers in Norway working on cell or gene therapy development
  • •Consortia spanning multiple disciplines and sectors (academia, clinical, industry)
  • •Projects at TRL 3-6, bridging early validation toward application
  • •Teams able to coordinate across the EP PerMed partnership structure

Key Dates

  • •Call opens 4 November 2026; pre-proposal deadline 20 January 2027
  • •Full proposal deadline 25 May 2027
  • •Two-stage process: pre-proposal then full proposal

Tips for Applicants

  • ✓Form the cross-sectorial consortium early since EP PerMed calls require partners beyond a single academic discipline or sector.
  • ✓Position the project clearly within TRL 3-6, proposals too early-stage or too close to market may not fit the call's scope.
  • ✓Use the pre-proposal stage to establish the consortium's interdisciplinary rationale before investing in a full technical proposal.

Frequently Asked Questions

What is the deadline for the Cell and Gene Therapy for Personalised Medicine call?

The pre-proposal is due 20 January 2027, with the full proposal deadline on 25 May 2027.

Is this call recurring?

No, it is listed as a one-off call.

Do I need a consortium to apply?

Yes, an interdisciplinary and cross-sectorial research consortium is required under the EP PerMed partnership.

What technology readiness level does this call target?

Projects should fall within TRL 3-6, covering early proof-of-concept through validation stages.

Who is eligible to apply from Norway?

Norwegian researchers participating in the required cross-sectorial consortium, as this call is funded through the Research Council of Norway.

cell-therapygene-therapypersonalised-medicineresearch-council-of-norwayep-permedconsortium-requiredtranslational-researchnorway
View full call →
Share ✉ Email X LinkedIn WhatsApp

Summary generated by AI based on published grant information. Always verify details on the funder's website.

Similar grants

Browse all open grants →

Browse Related

Closing in January 2027

Could Cell and Gene Therapy for Personalised Medicine be right for you?

See your personalised match score for this grant and others in 30 seconds. No signup needed to preview.

See my matches free →